1,3-二氢-5-(2-氯苯基)-2H-1,4-苯并二氮杂卓-2-酮 | 3022-68-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 中文名称: 1,3-二氢-5-(2-氯苯基)-2H-1,4-苯并二氮杂卓-2-酮
• 英文名称: 5-<2-Chlor-phenyl>-3H-1,4-benzodiazepin-2(1H)-on
• 英文别名: 1,3-Dihydro-5-(2-chlorophenyl)-2H-1,4-benzodiozepin-2-one；5-(2-chlorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one
• CAS: 3022-68-2
• 化学式: C₁₅H₁₁ClN₂O
• 分子量: 270.718
• InChiKey: DXAIBZTWPCDCFJ-UHFFFAOYSA-N

物化性质

• 熔点：
  212-213°C
• 密度：
  1.32

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1,3-二氢-5-(2-氯苯基)-2H-1,4-苯并二氮杂卓-2-酮 在 劳森试剂 作用下， 以 乙二醇二甲醚 为溶剂， 生成 5-(2-氯苯基)-1,3-二氢-1,4-苯并二氮杂-2-硫酮
  参考文献：
  名称：

  Pyrazolobenzodiazepines: Part I. Synthesis and SAR of a potent class of kinase inhibitors

  摘要：

  A novel series of pyrazolobenzodiazepines 3 has been identified as potent inhibitors of cyclin-dependent kinase 2 (CDK2). Their synthesis and structure-activity relationships (SAR) are described. Representative compounds from this class reversibly inhibit CDK2 activity in vitro, and block cell cycle progression in human tumor cell lines. Further exploration has revealed that this class of compounds inhibits several kinases that play critical roles in cancer cell growth and division as well as tumor angiogenesis. Together, these properties suggest a compelling basis for their use as antitumor agents. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.079
• 作为产物：
  描述：

  芬纳西泮 在 potassium fluoride 、 palladium diacetate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 6.0h， 以79%的产率得到1,3-二氢-5-(2-氯苯基)-2H-1,4-苯并二氮杂卓-2-酮
  参考文献：
  名称：

  An efficient debromination technique using PMHS with a number of ligands containing different functional groups

  摘要：

  DOI：

  10.24820/ark.5550190.p011.712

文献信息

• 3-(Substituted
  申请人：The Upjohn Company

  公开号：US03933816A1

  公开（公告）日：1976-01-20

  A compound of the formula: ##SPC1## Wherein R, R.sub.0, and R.sub.3 are hydrogen or alkyl of 1 to 3 carbon atoms, inclusive; wherein R.sub.1 and R.sub.2 are alkyl of 1 to 3 carbon atoms, or the group ##EQU1## together is pyrrolidino, piperidino, morpholino and N-methylpiperazino; wherein R.sub.7 is 2-pyridyl or a phenyl radical of the formula ##SPC2## Wherein R.sub.4 is hydrogen, fluoro, or chloro; wherein R.sub.5 is hydrogen or fluoro, with the proviso that R.sub.5 is not fluoro, when R.sub.4 is chloro; and wherein R.sub.6 is hydrogen, chloro, fluoro, bromo, trifluoromethyl, or nitro. The new compounds of formula II have tranquilizing and antianxiety activity and are thus useful to treat mammals and birds.

  一个化学式为：##SPC1##的化合物。其中R、R.sub.0和R.sub.3是氢或1至3个碳原子的烷基；其中R.sub.1和R.sub.2是1至3个碳原子的烷基，或者组##EQU1##一起是吡咯啉、哌啶、吗啉和N-甲基哌嗪；其中R.sub.7是2-吡啶基或化学式##SPC2##的苯基。其中R.sub.4是氢、氟或氯；其中R.sub.5是氢或氟，但R.sub.5不是氟，当R.sub.4是氯时；其中R.sub.6是氢、氯、氟、溴、三氟甲基或硝基。公式II的新化合物具有镇静和抗焦虑活性，因此对于治疗哺乳动物和鸟类是有用的。
• Novel benzodiazepine receptor partial agonists: oxadiazolylimidazobenzodiazepines
  作者：Frank Watjen、Raymond Baker、Mogens Engelstoff、Richard Herbert、Angus MacLeod、Anthony Knight、Kevin Merchant、Jonathan Moseley、John Saunders、Christopher J. Swain、Erik Wong、James P. Springer

  DOI：10.1021/jm00130a010

  日期：1989.10.1

  The synthesis and biochemical evaluation of a series of oxadiazole derivatives of imidazobenzodiazepines related to the benzodiazepine antagonist Ro 15-1788 (2a) are reported. Although the oxadiazole ring is seen as an isosteric replacement for the ester linkage, significant differences in structure-activity trends were observed. Specifically, oxadiazoles 9-12 invariably had increased receptor efficacy

  报道了一系列与苯二氮卓拮抗剂Ro 15-1788（2a）有关的咪唑基苯并二氮杂卓的恶二唑衍生物的合成和生化评估。尽管恶二唑环被看作是酯键的等排替代物，但观察到结构活性趋势上的显着差异。具体而言，相对于相应的酯，恶二唑9-12始终具有增加的受体功效（通过测量GABA位移证明）。另外，与经典的激动剂如地西epa形成鲜明对比的是，通过7-而不是8-卤素取代基增强了对苯并二氮杂receptor受体的亲和力。根据最初基于2a的X射线结构的六点受体结合模型讨论了结果。为了比较，确定了分别具有6-氧代和6-苯基基团的两种代表性恶二唑衍生物10h和12o的晶体结构，并将数据纳入了改良的结合模型中，以说明这些化合物的更高功效。结论是2a的拮抗行为取决于酯羰基氧的氢键受体性质，而对于恶二唑系列，该位点位于咪唑氮上。
• SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES
  申请人：Cook James M.

  公开号：US20100261711A1

  公开（公告）日：2010-10-14

  In preferred embodiments, the present invention provides methods of treatment and pharmaceutical compositions for the suppression, alleviation and prevention of seizures. The preferred embodiments of the present invention further relate to methods of treatment and pharmaceutical compositions using benzodiazepine derivatives that provide suppression, alleviation and prevention of seizures with reduced sedative and ataxic side effects.

  在优选实施方式中，本发明提供了用于抑制、缓解和预防癫痫发作的治疗方法和药物组合物。本发明的优选实施方式进一步涉及使用苯二氮䓬类衍生物的治疗方法和药物组合物，该类衍生物在减少镇静和共济失调副作用的同时提供了抑制、缓解和预防癫痫发作的效果。
• 6-(O-Halophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4]-benzodiazepine
  申请人：The Upjohn Company

  公开号：US04018788A1

  公开（公告）日：1977-04-19

  6-(o-halophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4]-benzodiazepines of the following formula: ##STR1## wherein the substituent "Hal" is either of the halogens having an atomic number up to 35, inclusive, i.e., fluoro, chloro or bromo, and their pharmacologically acceptable acid addition salts which are especially useful as muscle relaxing and anxiolylic agents.

  以下式子的6-(o-卤代苯基)-1-甲基-4H-s-三唑并[4,3-a][1,4]-苯二氮平，其中“Hal”取代基是原子序数为35及以下的卤素，即氟、氯或溴，以及它们的药理学上可接受的酸盐加合物，特别适用于肌肉松弛和抗焦虑药物。
• Method for treating neurocardiogenic syncope
  申请人：Creighton University

  公开号：US05706829A1

  公开（公告）日：1998-01-13

  The present invention relates to methods for treating neurocardiogenic syncope. The method involves administering to a patient an effective amount of a compound having the formula: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.5 are each selected from the group consisting of hydrogen and lower alkyl; and R.sub.3 and R.sub.4 are each selected from the group consisting of hydrogen, halogen, lower alkyl, nitro, amino, trifluoromethyl, and lower acylamino; at least one of R.sub.3 and R.sub.4 being a nitrogen containing group, or a pharmaceutically acceptable salt thereof.

  本发明涉及治疗神经源性晕厥的方法。该方法包括向患者施用一种具有以下结构式的化合物的有效量：##STR1## 其中R.sub.1、R.sub.2和R.sub.5分别选自氢和低碳基组成的群；而R.sub.3和R.sub.4分别选自氢、卤素、低碳基、硝基、氨基、三氟甲基和低酰胺基组成的群；其中R.sub.3和R.sub.4中至少有一个是含氮基团，或其药学上可接受的盐。